MedTrace Logo

Study of an Extended Release (ER) Tablet, Single and Repeated Dosing

NCT00689039 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2010-12-03

No results posted yet for this study

Summary

The purpose is to study the safety and tolerability of increasing doses of AZD1305 and how the medication is metabolised by the body (how it is taken up, distributed, and how it disappears from the body). The study is performed in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

AZD1305

ER tablet, administered as single and repeated doses.

DRUG

Placebo

Tablet, administered as single and repeated doses.

Sponsors & Collaborators

Principal Investigators

  • Helen Lunde, MD · AstraZeneca R&D, Mölndal, Sweden

  • Marianne Hartford, MD, PhD · AstraZeneca, Clinical Pharmacology Unit at Sahlgrenska University Hospital, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00689039 on ClinicalTrials.gov